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Abstract Genomic applications raise multiple challenges in-
cluding the optimization of genomic counseling (GC) services
as part of the results delivery process. More information on
patients’ motivations, preferences, and informational needs
are essential to guide the development of new, more efficient
practice delivery models that capitalize on the existing
strengths of a limited genetic counseling workforce. Semi-
structured telephone interviews were conducted with a subset
of counselees from the Coriell Personalized Medicine
Collaborative following online receipt of multiple
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personalized genomic test reports. Participants previously had
either in-person GC (chronic disease cohort, n = 20; mean age
60 years) or telephone GC (community cohort, n = 31; mean
age 46.8 years). Transcripts were analyzed using a Grounded
Theory framework. Major themes that emerged from the in-
terviews include 1) primary reasons for seeking GC were to
clarify results, put results into perspective relative to other
health-related concerns, and to receive personalized recom-
mendations; 2) there is need for a more participant driven
approach in terms of mode of GC communication (in-person,
phone, video), and refining the counseling agenda pre-
session; and 3) there was strong interest in the option of follow
up GC. By clarifying counselees’ expectations, views and
desired outcomes, we have uncovered a need for a more
participant-driven GC model when potentially actionable ge-
nomic results are received online.
Keywords Genetic . Genomic . Counseling . Practice
models . Service delivery . Complex disease . Qualitative
interviews
Introduction
Genetic counselors assess disease risks based on personal and
family medical histories, non-genetic influences, and genetic and
genomic information, in order to assist patients in medical and
other health-related decisions. Genetic counselors also attend to
the emotional ramifications of this information in a client-
centered and psychotherapeutic manner (Austin 2015; Kessler
1981; Veach et al. 2007). Traditional genetic counseling focuses
on a tailored discussion of one or a few disease or risk factors of
concern for the patient and their family. Often, this counseling is
done in-person, or more recently, by telephone (Cohen et al.
2013; Jacobs et al. 2016; Trepanier and Allain 2014). With the
emergence of technology that facilitates testing an individual for
hundreds or thousands of genomic risk variants at a single time
point, the traditional model for genetic counseling must naturally
evolve toward a more scaleable approach (Bernhardt 2014;
O’Daniel 2010; Ormond 2013; Roche 2012). Genomic counsel-
ing (GC) has been proposed to meet that need.
Genomic counseling is a health service designed to provide
comprehensive application of genetic and genomic information
to individuals and healthcare teams for prevention, improved
care, lifestyle changes, and treatment/preventative options
(Mills and Haga 2014; O’Daniel 2010; Ormond 2013; Shelton
and Whitcomb 2015). However, more information on patients’
motivations, preferences, and informational needs are essential
to guide the development of more efficient practice delivery
models that capitalize on the existing strengths of a limited ge-
netic counseling workforce. This transition does not replace the
vital work on risk assessment and counseling for single gene
(Mendelian) diseases, but builds upon it through careful
integration of polygenic and environmental risk information
for multiple disease risk indications. The complexity of genomic
information lends itself to innovative approaches that have the
potential to make GC more accessible and efficient, such as
online web portals providing high-quality education and support
in a more participatory and less healthcare provider time-
intensive fashion (Haga et al. 2014; Mills et al. 2014; Ormond
2013; Trepanier and Allain 2014). This more participatory ap-
proach has several benefits including meeting patients desire to
be engaged in their health care, and leading to improvements in
health outcomes (Simmons et al. 2014). Though several re-
search studies have been done around delivery of genomic in-
formation (Gordon et al. 2012; Haga et al. 2014;Mills and Haga
2014;Wright et al. 2014), the field of genetic counseling has not
yet articulated a model for GC that capatilizes on these technol-
ogies and actively involves patients, family members and phy-
sicians throughout all phases of the process.
As formative research for development of this model, we
conducted qualitative interviews with participants who previ-
ously received GC following online receipt of multiple poten-
tially actionable complex disease risk reports (e.g. age-related
macular degeneration) and drug-response reports (e.g.
CYP2C19 and Clopidogrel). The overarching goals of the
interviews were to: a) clarify patient expectations and impres-
sions of GC, b) determine the most and least valuable compo-
nents of a traditional, in person, genomic counselor driven
model and a telephone-based genomic counselor model for
which the participant helps determine, pre-session which ge-
nomic test results to discuss, and c) identify preferences for
follow-up counseling. In this paper we present major themes
from patient interviews and begin to outline an expanded
model of GC practice delivery based on study findings.
Methods
Participants of the Coriell Personalized Medicine
Collaborative (CPMC) received potentially actionable com-
plex disease and pharmacogenomic risk result reports through
a secure web portal (Keller et al. 2010). All participants pro-
vided saliva samples for genotyping and completed several
online surveys to produce personalized risk reports (Fig. 1)
that are based on genetic risk factors, family history, and non-
genetic factors (e.g. body mass index). Participants in this
study received results for up to 19 complex diseases (e.g.
age related macular degeneration, Table 1) and up to 7 drug
response reports (ex: CYP2C19 and Clopidogrel, Table 2).
Although most of the complex disease reports provide genetic
variant risk based on a single SNP, the relative risk spans a
wide range (0.08 - >6.0), and one report is polygenic (e.g.
exocrine pancreatic cancer, 3 SNPs). Participants could access
risk reports via a secure web portal, which also provides edu-
cational tools enabling participants to learn more about their
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risks and what they can do to positively influence their health.
The number of reports received by study participants prior to
receipt of GC, and prior to the qualitative interviews, varied
based on their route of accrual into the CPMC.
Results from primary outcomes of various trials related to the
CPMC have been previously reported (Gordon et al. 2012;
Schmidlen et al. 2016; Schmidlen et al. 2014; Sweet K, Sturm
A, Schmidlen T, McElroy J, Scheinfeldt L, Manickam K,
Gordon E, Hovick H, Roberts JS, Toland AE, Christman M.
(2016). Outcomes of a randomized controlled trial of genomic
counselling for patients receiving personalized and actionable
complex disease reports, unpublished). For this qualitative
interview study, participants were either from the Ohio State
University chronic disease cohort (OSU-CPMC) comprised of
individuals diagnosed with either hypertension or congestive
heart failure (n = 199) or the CPMC cohort. The CPMC cohort
included members of the general public (no selection criteria
related to health status; n = 4158), employees of the United
States Air Force Medical Service, including medical profes-
sionals and administrative staff, (n = 1290), and individuals with
either breast or prostate cancer enrolled through Fox Chase
Cancer Center (n = 86). Participants who had received GC in
either cohort were notified of the opportunity to participate in the
qualitative interviews via an email sent through the CPMC study
Fig. 1 Sample CPMC Coronary Artery Disease Report. Solid discs
represent the participant’s relative risk, and vertical cylinders depict the
range of RR values possible for the risk variable. On-line risk reports are
organized using a tabbed approach, with separate tabs for disease condi-
tion information, risk results, limitations, methods, and links to request
genetic counseling, or review educational material. To ensure readability,
the CPMC report design was informed by multiple rounds of pilot testing
conducted by allowing individuals with no scientific background to re-
view report drafts and provide feedback. The CPMC chose to report
relative risks to study participants because this approach allows for the
reporting of all disease risk factors (genetic, family history, and lifestyle)
using the same metric and does not require population estimates of dis-
ease incidence. The 8 CPMC health condition risk reports included in this
study present genetic variant risk based on a single SNP because of the
lack of validated multigenic models with robust prediction. Risk esti-
mates provided for non-genetic risk factors (family history and lifestyle
or environmental factors) were derived or reported from valid and repre-
sentative peer-reviewed publications. Non-genetic risk factors were in-
cluded if they meet two criteria: the risk factor must be collected by the
baseline required lifestyle questionnaire and the risk factor must be an
established disease risk, included in multiple disease review articles and
consistently associated with disease
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web portal. Two hundred and seven participants subsequently
contacted a study research assistant via email, and were provided
study details and a link to complete an eligibility survey. Fifty-
three participants subsequently completed an online consent
form and an interview by phone. One individual was removed
for participating twice and providing discrepant stories in her two
interviews. Thus, we had 51 telephone interviewees (20, OSU-
CPMC; 31, CPMC). This study was approved by Institutional
Review Board at each institution.
OSU-CPMC Participants
All 199 OSU-CPMC participants received an initial batch of
results pertaining to 8 health conditions (coronary artery disease,
type 1 diabetes, type 2 diabetes, hemochromatosis, melanoma,
age-related macular degeneration, prostate cancer, and lupus)
and 1 drug response report (CYP2C19 and Clopidogrel). They
were then randomized to and received in-person GC from li-
censed board certified Ohio State genomic counselors in a hos-
pital based setting. In-person GC consultations followed the
format of a traditional genetic counseling appointment, lasted
between 60 and 90min, and provided individualized risk assess-
ment for the nine initial personalized test risk reports. Given that
participants had the potential for multiple Bincreased^ risk var-
iables (genetic variant, family history and health behaviors,
Table 3), Bdecreased^ risk variant(s) for DM1, and differing
ranges of relative risk for each disease, a tabular one-page visual
display that summarized each of the risk factors into a quick
reference summary (QRS) was provided to OSU-CPMC partic-
ipants (Sweet et al. 2014). All individual increased risk variables
were highlighted, and risk was compared to the general popula-
tion risk for each disease. The genomic counselors also
reviewed, expanded and assessed the patient’s family history
to obtain at least a 3-generation pedigree, reviewed the patient’s
medical and social histories, environmental risk factor informa-
tion, and current health promotion and screening practices.
Specific actions to prevent and/or lower disease risk were also
provided. A detailedGC summary letter (Fig. 2) and PDF copies
of the nine personalized test reports were also generated for all
OSU-CPMC participants and their healthcare team, and was
made available within the EPIC electronic medical record.
Once OSU-CPMC participants completed all required study
activities, they received additional risk reports on a monthly
basis until all 26 reports were delivered online.
CPMC Participants
From study inception in December 2007 through January 2012,
study participants received all available CPMC reports when
genotyping was complete and then additional reports on an on-
going basis as they were created for inclusion in the study. For
participants enrolled starting in January 2012, CPMC participants
received results on an ongoing basis following study enrollment,
Table 1 19 Coriell Personalized Medicine Collaborative (CPMC)-
approved complex disease reports
Complex disease Reported SNPs
Age-related macular degeneration rs10490924
Bladder cancer rs9642880
Breast cancer rs2981582
Colorectal cancer rs6983267
Coronary artery disease rs1333049
Crohn’s disease rs11209026
Exocrine pancreatic cancer - polygenic rs3790844, rs401681,
rs4885093
Hemochromatosis rs1800562
Melanoma rs910873
Obesity rs9939609
Osteoarthritis rs3815148
Periodontitis rs1143634
Prostate cancer rs16901979
Rheumatoid arthritis rs6920220
Systemic lupus erythematosus rs3821236
Testicular cancer rs995030
Type 1 diabetes rs9272346
Type 2 diabetes rs7754840
Ulcerative colitis rs11209026
Table 2 7 Coriell Personalized Medicine Collaborative (CPMC) approved drug/drug class-gene pairs
Drug/drug class Gene(s) Reported SNPs
Celecoxib CYP2C9 rs72558189, rs1799853, rs9332131, rs28371685, rs1057910, rs2837168
Clopidogrel CYP2C19 rs12248560, rs28399504, rs41291556, rs72558184, rs4986893, rs4244285, rs72558186,
rs56337013
Metformin ATM rs11212617
Proton Pump
Inhibitors
CYP2C19 rs4244285, rs4986893, rs28399504, rs56337013, rs72558184, rs72558186, rs41291556,
rs17884712 , rs6413438, rs12248560
Simvastatin SLCO1B1 rs2306283, rs56101265, rs56061388, rs72559745, rs4149056,rs55901008, rs2306283, rs72559746
Thiopurines TPMT rs1142345, rs1800584, rs1800460, rs1800462
Warfarin CYP2C9/VKORC1/CYP4F2 rs1799853, rs1057910, rs28371686, rs9332131 , rs28371685, rs72558189, rs9923231, rs2108622
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no more frequently than 1 per month until all 26 study reports
were released. Telephone-based GC was available to all CPMC
participants, free of charge, but was not mandatory. Alternatively,
questions could be submitted to a genomic counselor via email.
Study participants may request GC at any time (pre- or post-result
receipt) however; all requests to date have come after results were
issued. All telephone GC is provided by a licensed board certified
genomic counselor employed by the Coriell Institute for Medical
Research. CPMC participants can submit requests for a GC ses-
sion as often as needed via email, by phone, or through the secure
CPMCweb portal. Telephone-based GC sessions are participant-
driven, meaning that the content of the counseling interaction is
primarily dictated by the specific questions and concerns of the
participant, with the genomic counselor providing appropriate
contextual information in Bteachable moments^ that arise
throughout the natural course of the conversation. Genomic coun-
selors only provided counseling for the (n = 26) test reports that
study participants received, and made referrals to other healthcare
specialists (e.g. ophthalmologist) or to a clinical genetic counselor
when warranted (e.g. participant family history suggestive of a
hereditary cancer syndrome). These telephone GC sessions on
average lasted approximately 27 min (range 10–65 min).
Table 3 Reportable disease risk values for a Caucasian OSU-CPMC participant
Disease Genetic variant RR Family history RR* BMI RR Smoking RR Diabetes*** RR
AMD 2.4, 6.0 4.0 NA 1.4a, 2.0b NA
CAD 1.3, 1.7 1.2F, 1.4 M NA 2.1 M,2.7F 1.7 M, 2.4F
DM1 0.08, 0.3 2.3; 6.6 NA NA NA
DM2 1.2, 1.3 1.9 2.3c, 5.9d NA NA
HH 1.0 M, 27.0 M** NA NA NA NA
LUP 1.4, 2.0 4.1, 11.3 NA 1.0a, 1.5b NA
MEL 1.7, 3.0 2.2 NA NA NA
PRO 1.5 M, 1.5 M 1.9 M NA NA NA
AMD Age Related Macular Degeneration
CAD Coronary Artery Disease
DM1 Type 1 Diabetes
DM2 Type 2 Diabetes
HH Hemochromatosis
LUP Systemic Lupus Erythematosus
MELMelanoma
PRO Prostate cancer
RR Relative Risk
NA not applicable risk factor
M Male
F Female
a former smoker
b current smoker
c BMI = 25.0–29.9 kg/m2
d BMI = ≥ 30 kg/m2
*Positive family history defined as follows:
AMD one or more first-degree relatives with age-related macular degeneration
CAD one or both parents diagnosed with coronary artery disease
DM1 one (RR 2.3) or more (RR 6.6) first-degree relatives diagnosed with type 1 or type 2 diabetes
DM2 one or both parents with type 2 diabetes
LUP one (RR 4.1) or two or more (RR 11.3) first-degree relatives with a history of any of the following autoimmune diseases: Systemic lupus
erythematosus (SLE/lupus) , Sjogren’s syndrome, rheumatoid arthritis, vitiligo, multiple sclerosis, celiac disease, type 1 diabetes (IDDM), autoimmune
hyperthyroidism-Grave’s disease, autoimmune hypothyroidism, Crohns disease, ulcerative colitis and psoriasis
MEL one or more first-degree relatives with melanoma
PRO father and/or any brothers diagnosed with prostate cancer
**RR only provided to males. Male heterozygotes and homozygote wild type received an RR of 1.0; females got absolute risk: homozygotes received
16 % lifetime risk, heterozygotes and wild type homozygotes received a lifetime risk of 1 %
***Both Type 1 and Type 2 diabetes
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Phone Interviews
Phone interviews were conducted by LW, who was trained
to conduct the interviews by EG and TS who are experi-
enced interviewers and qualitative researchers (Gollust
et al. 2012; Gordon et al. 2012; Schmidlen et al. 2014).
The interviews used a semi-structured guide (Supplemental
Table 1) which contained questions designed to determine
participants’ expectations and experiences with GC, the
characteristics of their GC session and nature of their
results, as well as their expectations and preferences re-
garding GC communication and topics. We also assessed
the extent to which participants shared results with their
family members and/or health care providers. The inter-
view guide was pre-tested with 5 study participants who
had received GC to make additional edits for clarity, de-
termine the length of the interview, and to ensure that the
interviewer (LW) had received adequate training.
Interviews lasted 45–90 min and participants received a
$50 amazon.com e- gift card for participating.
Fig. 2 Sample GC summary
letter
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Data Analysis
Phone interviews were recorded and transcribed verbatim.
Transcripts were analyzed using NVivo 9 using a deductive
coding method. Transcribed interviews were first read as a
whole by the research team (KS, TS, AS, LW, KW) and mar-
ginal notes were made of major concepts and themes that
emerged in grounded theory format. An initial codebook was
developed (KS, TS, ACS, KW, BAB, ESG) including major
codes and sub-codes, which captured key thoughts or concepts
from the interviews. KW, SH and KS, working together,
discussed the category definitions, individually coded a portion
of the interview transcripts, and subsequently reviewed this
work to test reliability. Category definitions were then revised
after this pre-testing to harmonize the approach to coding. They
assigned codes and revised the codebook as necessary using
NVivo. Results of descriptive coding were then organized into
major and minor themes to better understand participant expec-
tations and impressions of the GC process, parts of the separate
service delivery model(s) that worked well and those that need
modification, and preferences for follow up GC.
Results
Participant Characteristics
Participant demographics are presented in Table 4. The ma-
jority of participants were white and highly educated; most
had incomes greater than $75,000 per year. Of the 51 partic-
ipants, there were five who worked in health care related oc-
cupations (3 physicians, 2 nurses).
In total, 91 (45.7 %) OSU-CPMC participants received in-
person GC between August 2011–May 2014 as part of the
randomized trial. For participants in this qualitative interview
study (n = 20), the average number of disease reports viewed
at the time of in-person GC was 6.9 (range: 1–10) and the
number of PGx reports was 1.7 (range: 0–3). By the time of
the interviews (May–July 2014), an average of 8.6 complex
disease reports (range: 4–18) and 2.7 PGx reports (range: 0–5)
had been viewed. The mean number of days between counsel-
ing and the phone interviews was 427 (range: 23–966). The
mean age of OSU-CPMC study participants was 60 years
(versus 46.8 years in the CPMC cohort).
Table 4 Demographics
OSU-CPMC CPMC P-value Test
N 20 31
Mean age (SE) 60 (2.03) 45.68 (2.51) 0.00005 Welch’s T-test
Education High school graduate 0 1 0.2572 Fisher’s exact test
Some college 3 2 0.0738 Ordinal Logistic Regression
Associate degree 4 2
Bachelors degree 7 9
Graduate degree 6 17
Annual household income Less than 25,000 2 1 0.03345 Fisher’s exact test
25,000 to 49,999 4 2 0.774 Ordinal Logistic Regression
50,000 to 74,999 1 11
75,000 to 99,999 3 4
More than 100,000 8 13
NA 2 0
Race Asian 0 1 1 Fisher’s exact test
Black or African-American 1 1
White (Caucasian) 19 29
Gender Female 10 24 0.06765 Fisher’s exact test
Male 10 7
Healthcare practitioners Licensed Practical Nurse 0 1
Registered Nurse or BSN 0 1
Physician 0 3
Non-healthcare Occupations Other 20 26
OSU-CPMC Chronic Disease cohort receiving in-person GC
CPMC CPMC cohort receiving telephone GC
Fisher’s exact test
Ordinal Logistic Regression
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Overall, 191 of 5534 (3.5 %) CPMC participants opted to
have telephone GC. For CPMC interviewees in this qualita-
tive study (n = 31), an average of 10.9 (range: 2–19) disease
reports and 3.1 PGx (range: 0–5) reports had been viewed
upon receipt of telephone GC. By the time of the qualitative
interviews (May–July 2014), 14.6 disease reports (range: 5–
19) and 4.3 PGx reports (range: 0–7) had been viewed
(Table 5). The mean number of days between counseling
and the phone interviews was 320 (range 7–1189).
Major Themes
There were a number of major themes that emerged from
the interviews, including participants’: (1) diverse reasons
for participating in GC; (2) positive impressions of GC,
independent of the communication channel (in-person
versus phone), (3) desire for a more participant-driven
model for GC and (4) stated need for follow-up GC as
new results become available. We present these major
findings in greater detail below.
Diverse Reasons for Participating in GC When asked
about their reasons for seeking GC, the most common rea-
son stated amongst participants in both groups (in-person
and phone counseling) was to clarify testing results in
more detail [n = 28 (54.9 %) participants: 15 (75 %) in-
person, 13 (41.2 %) phone]. While only 13 participants [7
(35 %) in-person, 6 (16.1 %) phone] felt the complex dis-
ease test reports were too technical, about two-thirds
[n = 33 (64.7 %) participants: 11 (55 %) in-person, 22
(71 %) phone] said there was at least one result that was
difficult for them to understand. One participant noted that
she desired counseling, Bto go through the results in detail
and help me understand how these results affected my ev-
eryday life^ (OSU-CPMC, female, age 61). Another par-
ticipant noted that the counselor was able to give her, B… a
little bit more explanation or to make sure that what I ex-
plained to her or how I thought I was reading it that it was
correct or not^ (CPMC, female, 33).
Participants also sought GC to gain a better understanding
of the interaction of multiple risk factors (genetic variants,
family history, non-genetic risk factors) on their reported dis-
ease risk. One participant said she joined the study because of
the option to see a genetic counselor and noted it was impor-
tant to Bhave somebody with expertise to really give me the
insight on what it all means and how it all fits together was
what I was looking for^ (OSU-CPMC, female, age 54).
Another said that her counselor Bgave me a tremendous
amount of interpretation. It was just very helpful to me. He
was able to say well look, this is what this means^ (OSU-
CPMC, female, age 68). Close to 70 % of participants in both
groups explicitly remembered the counselor talking about
gene/environment interactions, and how multiple factors in-
fluence risk for a given disease [n = 35: 14 (70 %) in-person,
21 (67.7 %) phone]. As one participant noted, Bthere’s so
many factors involved with diabetes, and weight, and age,
and you know, gender, and history, family history, genetic
variants, multiple genetic variants. I found that one to be a
little bit more confusing. I do have a family history of that,
so I just wanted to make more clear perhaps my likelihood
based on the genetic results of me getting it with my family
history^ (CPMC, male, age 39).
Participants often asked [16 (80 %) in-person; 17 (54.8 %)
phone] for concrete, specific ideas and recommendations to
assist them in taking appropriate action in response to the test
results. For example, Bwhich are the things I need to be most
concerned about, or most aware of, or most make sure I dis-
cuss with my physician, whether that means I am at more of a
genetic risk in the future or there is something I can do envi-
ronmentally, you know, to change it. To me, what are the
action items?^ (OSU-CPMC, male, age 46). Another counsel-
ee said, BBut it would have been more reassuring if there was
some way that they could say well; I’m telling you how to be
proactive, other than to talk to your doctor^ (CPMC, female,
age 68). Almost two-thirds of participants [n = 33: 16 (80 %)
in-person, 17 (54.8 %) phone] said the counselor made spe-
cific behavioral recommendations (e.g. exercise or lose
weight) in response to the risk information; however, some
thought they would receive more of an action plan for
behavorial recommendations. For example, one participant
said that she Bthought that I would receive more of a game
plan than I got^ (CPMC, female, age 68).
Table 5 Number of complex disease and pharmacogenomics reports viewed
OSU-CPMC Mean # complex disease reports Mean # pharmacogenomic reports
By the time of in-person GC 6.9 (range: 1–10) 1.7 (range: 0–3)
By the time of phone interview 8.6 (range: 4–18) 2.7 (range: 0–5)
CPMC
By the time of telephone GC 10.9 (range: 2–19) 3.1 (range: 0–5)
By the time of phone interview 14.6 (range: 5–19) 4.3 (range: 0–7)
OSU-CPMC Chronic Disease cohort receiving in-person GC
CPMC CPMC cohort receiving telephone GC
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Positive Impressions of Counseling In general, participants
had positive impressions of GC, independent of the means
of service delivery (telephone versus in-person). The ma-
jority of participants said they were satisfied with their GC
experience and that it exceeded their expectations [n = 48;
19 (95 %) in-person, 29 (93.5 %) phone]. One-third of
respondents [n = 17: 9 (45 %) in-person, 8 (25.8 %) phone]
mentioned that the GC helped put their results into per-
spective (e.g., what their risk was compared to the general
population; how family history vs. genetic variant vs. en-
vironmental risk factors like body mass index play a role
and to what extent; and why they have certain conditions in
their family, or not). Many, especially those receiving
participant-driven phone counseling, raised unsolicited
positive comments regarding GC, stating that their coun-
selor took the time to listen to them and answer questions
in a spontaneous fashion [n = 35: 11 (55 %) in-person, 24
(77.4 %) phone]. However, slightly more individuals re-
ceiving in-person counseling (12; 60 %) than phone
counseling (n = 10; 32.3 %), thought their counseling
was thorough and provided complete information; this
finding is likely attributable to the more intensive GC-led
in-person session for the chronic disease cohort. As one
counselee noted, BI just came away with a much better
understanding, not only about genetic counseling, but also
about myself and my risk to stuff and my health and how to
better communicate with my doctors at appointments.^
The participant also noted that her doctors Bdon’t have time
in a 20 or 30 minute appointment to talk about our family
history, and go over whatever it is that we came to see, and
add that all into the bigger picture. It just is something that
gets lost sometimes^ (CPMC, female, age 32).
Desire for a More Participant-Driven Approach in Terms
of Mode of GC Communication, and Agenda In asking
participants about preferences regarding means of service de-
livery (e.g. in-person, telephone), we found that participants
often liked the format of GC they had received. For example,
74 % (n = 23) of those who said they preferred telephone GC
received phone counseling. One participant said, BOver the
phone was fine and probably preferable just based on schedul-
ing convenience. I don’t think there’s any benefit in doing it
face-to-face. I think maybe in-person, you’d have less compli-
ance, because people don’t want to have to take time out of their
day to drive somewhere, and then wait, and then go in.^ Some
did prefer a modality other than the one they received, however.
Six participants who received phone counseling stated a pref-
erence for in-person, and two were fine with either format. As
one of these counselees noted, BJust like talking to another
human being and just being there. It can be like comforting.
Like you know, the counselor is there to sort of, you know, help
read off of you and help you^(CPMC, female, age 57).
Participants were also asked whether online counseling (via
Skype or other video chat provider) would be a viable option
and about half [9 (45 %) in-person, 17 (54.8 %) phone] agreed
that it would, stating that Bvideo chats give you that face to face
option and phones don’t^ (OSU-CPMC, male, age 52). Phone
counselees, in particular, were more open to mediated commu-
nication (phone or online) than those in the in-person cohort.
Some felt [n = 8 (30.8 %): 2 in-person, 6 phone] having a
combination of methods (e.g., view results online while talking
to the counselor) would be helpful. However, delivery method
may ultimately depend on the severity and risk level of the
information being communicated. As one participant ex-
plained, Bif the genetic counseling comes up, say Mr. ___ has
no risk for diabetes type 1 or 2 let patients access it right online
like they do now. But if Mr. ___ has a three time risk for
diabetes I think that deserves counseling, regardless. So I don’t
know that I would give the option of allowing somebody who
has a significant medically actionable disease the option of
looking at it themselves^ (CPMC, female 54).
We identified a need for more flexibility in determining the
structure and direction of the GC session, and of results dis-
closure. Most participants [n = 48 (17 (85 %) in-person, 31
(100 %) phone)] thought the GC session was Bjust right^ in
terms of length. The OSU-CPMC chronic disease participants
often said the in-person sessions were led by the genomic
counselor (n = 11; 55 %), while many in the phone counseling
group felt the session was led by the participant (n = 12;
38.7 %) or was jointly led by the participant and the counselor
(n = 8; 25.8 %). As one telephone participant noted, BI didn’t
notice that there was a very structured format to it but maybe
there was. But whatever it was, it worked. She talked for as
long as necessary to answer my questions and have a good
discussion about the topic.^ (CPMC, female, age 41). Some
participants also said they would like to help choose, pre-ses-
sion, the areas of focus for the GC session (e.g. discussion of
specific test results). For example, BI communicated by email,
you know, to set it up, and told her the specific areas so I
wouldn’t have expected her to go beyond that. And that was
my, you know…, she met my expectations^ (CPMC, male,
age 25). In-person counselees [n = 15 (75 %)] had greater
preference for going over all available test reports. As one
participant noted, BI think it would be helpful to go over all
of them, because… to kind of say that, look, alright, you can’t
ignore these other ones either. I mean they’re helpful, because
you know, you might want to keep tabs on these to kind of
remember…^ (OSU-CPMC, male, age 35). However, this
finding might be related to underlying health concerns, or
the flow of test reports release through the web portal for each
cohort as the converse was true for telephone counselees [n =
16 (51.2 %)] who often only wanted to discuss increased risk
results. Telephone counselees had on average received more
reports at the time of GC: CPMC, 10.9 disease reports (range:
2–19) and 3.1 PGx reports (range: 0–5); OSU-CPMC, 6.9
disease reports (range: 1–10), 1.7 PGx reports (range: 0–3).
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As one CPMC participant (female, age 58) noted, BSomebody
else might not mind, but personally, I don’t want all of the
results, but if there was something that is flagged in his or her
mind, I wouldn’t mind them reviewing it with me.^
Web Portal and Tools for GC Sessions Generally, people
liked the CPMC test report content and the web portal where
they accessed the information, as well as risk communication
tools such as visual aids. BI’m going to say that the causes
were helpful, the how common graph. I like the risk summary
(Fig. 1). So what I like about the risk summary is it kind of
separates out by risk. And I can clearly see on that graph
where each of those, the family history and other risk factors
such as for the one I’m looking at is smoking. The genetic
variant, it’s just at a glance I can tell how much genetics plays
into the role versus maybe some other risk factors^ (OSU-
CPMC, female, age 54). Most OSU-CPMC counselees (14;
70 %) recalled the in-person GC summary letter (Fig. 2). For
example, BBesides just again reinforcing everything, having it
really kind of summarized in just a few page document, the
history, the risk assessment, the… kind of the increased risk,
tying in the family history as well as the genetic testing into
one nice tidy little summary here, and the recommendations,
was just nice to have it all in one small package^ (OSU-
CPMC, male, age 56). Also, many liked the idea of having
additional Btools/resources^ available for use pre- and post-
session including a concise BSummary Report^ that highlights
what the participant is at increased (or decreased) risk for, and
what the risk estimate is based on. Participants in both groups,
liked being able to see their results while talking to the coun-
selor: BLet’s say an interactive with the counselor present and
maybe a visual of some kind on the computer. Or an explana-
tion with the sense the person’s here, also watching this with
me. And I can question him or her as to exactly what is need-
ed, etc^ (OSU-CPMC, male, age 67).
Interest for Follow-up It was notable that 90 % of inter-
viewees in both groups were interested in having the option
of follow up with the genomic counselor as more results be-
came available. As one counselee noted, Bas much as you try
to bone up on a subject and make sure that you understand
everything there’s always that little pang of doubt that you’re
misreading something. Especially if the results are a little dif-
ferent than what you would have thought or if your interpre-
tation is boy, the last results were great, but this one I’m not so
sure about. Just having the option to reach out to somebody, to
go back a little bit, maybe that’s a time where sending an email
would be good enough. Saying hey, I’m reading this result and
I’m not sure I’m reading it right. Can you maybe clarify?^
(OSU-CPMC, male, age 52). Preferences for mode of
follow-up were primarily telephone or in-person in both
groups. There were also some participants who felt
performing GC in one format, and then having the option of
choosing a different counseling modality as new results be-
came available was appealing. As one in-person counselee
suggested, Ban initial meeting with a genetic counselor to ex-
plain what your risk factors are, what the markers mean, and
then anything after that when they add something to your list,
then maybe phone, maybe internet.^ In contrast, a phone
counselee suggested that Bquestions could be answered by
email first and then, if the results were complicated, the par-
ticipant could request a phone counseling or face-to-face
interview^ (CPMC, female, age 29).
Discussion
Clinical application of genomic technologies raises multiple
challenges including communicating large amounts of action-
able genetic variant information in the context of additional
non-genetic risk information to patients in a way they can
readily understand, apply currently for health promotion and
possibly treatment, and utilize over the lifespan (Ashley 2015;
Collins and Varmus 2015). More accurate disease risks esti-
mates, for both highly penetrant Mendelian conditions and
common, complex diseases are becoming more readily avail-
able (Collins and Varmus 2015; Khoury and Evans 2015).
Accordingly, further availability of genetic and genomic
counseling services within the results delivery process to pa-
tients will be essential and directly applicable for new large-
scale genomic sequencing efforts (Collins and Varmus 2015;
Kaufman et al. 2012; Select Committee on Science and
Technology 2009). Currently very little is known about how
participants offered either in-person or telephone genomic
counseling for multiple common diseases with actionable
components perceive its potential benefits. This is important
to understand since most previous studies show around 10 %
or less uptake of counseling for genomic based results re-
ceived through online delivery (Bloss et al. 2013; Kaufman
et al. 2012; Schmidlen et al. 2014). Results from this study
provide a number of key into insights regarding participant
expectations and desired effects from genomic counseling
and illustrate the need for a more participant-driven model
of GC. These results provide an important vantage point to
further develop models of counseling service delivery for ac-
tionable genomic based on results received online (Kaphingst
et al. 2012; Mills et al. 2014; Simmons et al. 2014).
The essential themes which emerged from the interviewees
were the desire through genomic counseling to clarify test
results, put results into perspective relative to other health-
related and environmental risk factors, and to receive person-
alized recommendations. Participants also were interested in
greater explanation regarding the interaction of multiple influ-
ences (genetic variants, family history, lifestyle/environment)
on common disease risk. The frequency with which inter-
viewees recalled the counselor discussing the influence of
Counselees’ Perspectives of Genomic Counseling Following Online 747
multiple risk factors on the development of common diseases
suggests that discussing the genetic and environmental contri-
butions together, in a holistic fashion, may provide a unique
opportunity to provide education regarding healthy behaviors.
Our approach to counseling has been to focus on the influence
of both genes and environment on disease development, es-
pecially given the context of multiple test results that provide a
wide range of disease risk and actionable components.
However, from the interviews it was not clear (in either group)
whether people thought about multiple diseases together and
the relationships between them (e.g. diabetes as a risk factor
for development of cardiovascular disease), or focused on one
disease at a time. Focusing the counseling on the natural his-
tory of a given disease, especially in light of modifiable life-
style changes, may assist with development of a personalized
action plan (Mills and Haga 2014; Shelton and Whitcomb
2015). Although respondents often recall the counselor mak-
ing specific behavioral recommendations (e.g. exercise or lose
weight) in response to the risk information, this portion of the
practice model requires more attention. Although most previ-
ous studies document that knowledge of genetic risk for com-
mon disease does not lead to behavior change (Hollands et al.
2016), none of these prior studies attempted to increase par-
ticipant understanding of risk or help facilitate behavior mod-
ification (i.e., providing referrals) via genomic counseling for
a range of actionable multifactorial disease risks as did the
current study. Providing insight on the varied effect of geno-
mic risk variants through counseling, to include the limited
predictive contribution of many of these variants, and the
polygenic and multifactorial nature of common disease risk,
may allow individuals to develop more accurate perceptions
of and appropriate responses to genetic risk for common dis-
eases. Further supplementing our counseling approach with
effective health behavior recommendations and interventions
(Austin 2015), perhaps with use of more directive and moti-
vational counseling, may lead to adoption of health behaviors
leading to risk reduction (Mills and Haga 2014; Shelton and
Whitcomb 2015). The inclusion of health coaches and/or
nurses for additional patient support and chronic disease inter-
vention may also be beneficial (Bennett et al. 2010; Shelton
and Whitcomb 2015), though further research is needed.
Although participants in both groups tended to feel satis-
fied with the type of counseling they received, the approaches
to GC used in this study need to be developed further. Our
results suggest there is a need for more flexibility in determin-
ing the format of results disclosure and GC delivery, and for
follow up counseling. For example, many of the chronic dis-
ease participants receiving in-person counseling had prefer-
ence for discussion of all available test results, while the con-
verse was true for the community participants, who, for the
most part only wanted to discuss increased risk results. This
difference may be due to the the structure of the in-person GC
sessions, which focused on all nine initial test reports, whereas
telephone participants had more control over which reports
(up to 26) to view and discuss. It might also be attributable
to the fact that those receiving in-person counseling in a med-
ical care setting were already dealing with a chronic dis-
ease(s). It is notable that for both groups, telephone counseling
would be acceptable when presenting personalized genomic
results. Both groups also liked being able to visualize their
results through the web portal while talking to the counselor,
and felt positively when they had time to ask questions and
when the counselor took time to listen to them. This suggests
that formats whereby the participant may help direct where the
conversation might go during the genomic counseling session
is important, and that promotion of technologymediated chan-
nels of communication (e.g. texting; email; video conferenc-
ing; social networking) might be beneficial (Cohen et al.
2013). Assessing participant preferences prior to the counsel-
ing appointment, perhaps through technology mediated com-
munication, may assist in refining the counseling agenda, es-
pecially in light of the online return ofmultiple test results, and
to allow for follow up counseling for new results or questions.
Taken together, our results suggest that what patients desire
is the ability to provide counseling preferences prior to the
actual delivery of genomic counseling. Based on our results
and to also help increase efficiency and potential effectiveness
of genetic/genomic counseling, we propose assessing patient
preferences for communication modality (telephone,
telegenetic or in-person) prior to counseling. Utilization of
technology beyond the standard Bin-person^mode of counsel-
ing may help facilitate patient access to services that are lim-
ited due to geographical or financial barriers, or when in-
person counseling is not feasible (Trepanier and Allain
2014), and these alternative service deliverymodels have been
well-accepted by patients (Buchanan et al. 2016).
Furthermore, these alternate forms of communication increase
patient/client convenience, and expand the scope of practice to
include the ability to counsel multiple family members simul-
taneously who are not all in the same geographic location
(Cohen et al. 2016; Trepanier and Allain 2014).
Second, given patients’ desire for flexibility in GC versus a
standard scripted approach for all patients, we propose that an
assessment of patient areas of concern, and/or points of dis-
cussion for the counseling session can be performed with the
use of question prompts that could be emailed or texted to the
patient pre-session. Having the counselee provide these pref-
erences pre-session allows for even more pointed contracting
and more specific case preparation. This may increase geno-
mic counseling efficiency, and facilitate targeted psychother-
apeutic interventions. This is especially relevant when an in-
dividual is provided results for multiple disease risks as well
as pharmacogenomics results. Moreover, because counseling
for common risk variants may not always require advanced or
specialized counseling from a genetic counselor, health care
professionals, with supplemental training in genetics/
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genomics (e.g. nurses) could use similar approaches to per-
sonalized and targeted genomic counseling (Mills and Haga
2014; O’Daniel 2010; Ormond 2013; Shelton and Whitcomb
2015). The goal of GC should be to make sure patients under-
stand the information that is relevant to their health. As such,
genomic counselors should recognize that the degree of GC
intervention needed will vary per patient, and per indication,
such that some participants may need counseling for multiple
risks, while others may understand that concepts required for
the interpretation of results for one condition are also relevant
to the interpretation of other results.
Although the receipt of multiple personalized genomic re-
sults through a web portal in the context of genomic counseling
was well received, our results suggest that there remains oppor-
tunity for improvement in terms of the management of the
different types of test reports received, and improvement in test
report communication. Refinement of the test report makeup
and web materials with inclusion of graphs and visuals (e.g.,
pictographs) with less focus on actual numbers could drive
home concepts of risk and encourage more viewing of test
reports (Lautenbach et al. 2013). Further modification of sum-
mary reports, and summary letters, their format and content,
and the way in which this is delivered to the participant and
their healthcare team would be beneficial (Sweet et al. 2016). It
would be ideal to develop a summary report with explicit
breakdown of the areas of risk (e.g. non-genetic versus genetic)
for a particular disease to allow for the viewing and discussion
of management of multiple types of risk information at once,
including hyperlinks for greater detail or to external resources
to make the process more dynamic (Vassy et al. 2015), and to
allow for more active routing and delivery. The growing avail-
ability and accessibility of information technologies (e.g. hand
held devices), as well as innovative health communication ap-
proaches (e.g. increased access to information and support on
demand to include enhanced opportunity to interact with health
professionals, or identify support through the use of networking
technology; tailoring information to the specific needs or char-
acteristics of an individuals or groups of users) (Hovick et al.
2014; Robinson et al. 1998), could be used to accentuate the
current CPMC web portal route of genomic results delivery. It
could also provide opportunity for education and support in a
more participatory and less healthcare provider time-intensive
fashion (Chow et al. 2015; Mishra et al. 2016; Robinson et al.
1998).
There are several limitations associated with this study.
This study reports on a small set of qualitative interviews
conducted with a self-selected predominantly Caucasian, gen-
erally well-educated population recruited to a parent study
either by being a 1) patient with chronic heart disease at a
large academic medical center, or 2) community, cancer, or
military medical service employee participants who sought
genomic testing on their own. Those who received telephone
counseling (CPMC participants) did so at their own request,
thus they may have a different motivation level or interest in
genomic counseling than the OSU-CPMC patient participants
who were assigned to receive in-person genomic counseling
as part of a randomized controlled trial. In addition there are
several differences between these groups that may have con-
tributed to the trends that were observed. The OSU cohort was
older (mean 60 yrs. vs 45 in the CPMC cohort). This age
difference could have contributed to comfort with technology,
availability for in person appointments, etc. In addition, the
length of the appointment was significantly different with the
phone counseling averaging 27 min and the in-person
counseling sessions which were at least 60 min. It is not
known how participants in either group would have responded
to the mode of counseling had the approach been consistent.
Furthermore, as interviews were only conducted with coun-
selees, comparisons were not made to individuals who did not
receive GC, and who may have different views.
Although our findings provide insight into needs for the
genomic counseling process among multiple users, more
work needs to be done. The fact that our current GC practice
model focuses onmultiple actionable disease reports delivered
through online format, with each disease risk based on several
influences (e.g. genetic risk variant(s), family history, environ-
ment/lifestyle), and promotes personal health behavior modi-
fication on three essential socio-ecological levels (individual,
receiving online actionable genomic results; interpersonal, in-
teraction with a GC; and organizational, interaction with
health care systems (Division of Cancer Prevention and
Control 2015; Golden et al. 2015), makes this an applicable
model moving forward. Incorporation of more comprehensive
genomic risk scores, based on multiple risk variants for both
common and rare (Mendelian) disease, will allow for a GC
model that is adaptable and scalable for application in diverse
clinical and research settings. The findings presented here
provide a basis for expansion of this approach to genomic
counseling which is participant driven in mode of communi-
cation (phone, video, in person) and agenda. Given the
breadth of genomic information likely to be included in geno-
mic testing reports as the use ofWES/WGS increase, this non-
traditional approach to genetic counseling (genomic counsel-
ing) will be necessary to construct a practice model that will
help respond to increasing demands, worldwide, of the genetic
counseling and next generation sequencing fields (Bernhardt
2014; Khoury et al. 2013; Manolio et al. 2015; O’Daniel
2010; Ormond 2013).
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